Intellectual Property Litigator Speaks on Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

Intellectual property litigation partner Kevin Post (New York) spoke on “The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning” on April 24 at The American Conference Institute’s (ACI) 11th annual “Paragraph IV Disputes” conference in New York.

The ACI panel was moderated by Mintz Levin Member Kathleen Carr and included co-panelists Pfizer Inc. Vice President & Assistant General Counsel Jeffrey Myers, Ironwood Pharmaceuticals Vice President & Chief Intellectual Property Counsel Karen Brown, and FTI Consulting Senior Managing Director Vince Thomas.

The panelists addressed topics including new IP and economic due diligence strategies for brand name and generic manufacturers in view of current legal considerations and market trends, how the current stage of the patent cliff, the alternative litigation route at the Patent Trial and Appeal Board (PTAB) and new federal court jurisprudence have reshaped Hatch-Waxman strategies, and how companies can deal with new economic considerations through creative budgeting and alternative fee arrangements.